AlphAIalphai — Financial news for AI agents
GuruFocusAPR 104 min read$MGNX

Today's Analyst Rating Data for MGNX: Major Upgrade by B. Riley

B. Riley Securities has upgraded Macrogenics (MGNX) from Neutral to Buy, significantly increasing its price target from $3.00 to $9.00, suggesting a 200% growth potential. This upgrade reflects a shifting positive sentiment for the clinical-stage biopharmaceutical company, which focuses on developing antibody-based therapeutics for cancer using various modalities. Despite the upgrade, the average analyst price target for MGNX is $4.00, with a consensus "Hold" status from seven brokerage firms.

Original reporting
GuruFocus · GuruFocus News
Published Apr 10, 2026, 6:39 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Apr 10, 2026, 7:31 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefFinancial news
Primary signal
$MGNX
Bullish
medium confidence
Mentioned
$MGNX
alphai data visualization · based on GuruFocus
Decision brief

The 30-second read

$MGNXBullishMed
01

Why it matters

The upgrade could lead to increased trading volume and short-term price appreciation, but long-term success depends on clinical trial results and market acceptance.

02

Market read

The news is highly relevant for biotech investors and traders focusing on clinical-stage companies, with potential sector-wide implications.

03

What to watch

Potential delays in clinical trials, regulatory hurdles, or broader market downturns could negate the positive sentiment and lead to price declines.

Timing: Immediate to short-term (next 1-3 months)

Background

MGNX is a clinical-stage biopharmaceutical company focusing on antibody-based cancer therapeutics, which are highly sensitive to clinical trial outcomes and regulatory decisions.

Company-level read

Ticker impact

$MGNXBullishMedium confidence
Context

High relevance due to recent analyst upgrade and significant price target change.

Expected impact

Moderate to high upward movement in the short term, possibly 20-30% over the next 1-3 months, contingent on market conditions and company performance.

Evidence & confidence

The upgrade reflects analyst confidence but is tempered by the low average analyst price target and mixed industry sentiment. Technical indicators and liquidity should be analyzed further for precise timing.

Market effects

Sector

Potential positive impact on biotech and life sciences sectors, especially companies with similar clinical-stage profiles.

Regional

Limited regional impact; primarily relevant to US biotech investors.

Global

Moderate; reflects sector-specific optimism but not broad market shifts.

Counterpoint

What could challenge this read

The analyst upgrade may be overly optimistic, and the low average analyst price target indicates skepticism about the company's near-term valuation.

Key entities

  • Company
    Macrogenics (MGNX)

    A biopharmaceutical company developing antibody-based therapeutics for cancer.

  • Financial Institution
    B. Riley Securities

    An investment bank that issued the recent analyst upgrade.

Read at source← All news

Related articles

AUG 11
$MGNXMed

MacroGenics stock rises on $10M Gilead option exercise

MacroGenics (NASDAQ:MGNX) shares rose 4.3% after hours after Gilead Sciences exercised an option on a preclinical bispecific program under their 2022 collaboration, triggering a $10 million payment. Gilead holds an exclusive license using MacroGenics’ TRIDENT platform targeting two undisclosed solid tumor targets. MacroGenics may receive up to about $1.6 billion more in milestones and royalties.

investing.com2 min
JUL 7
$MGNXMed

MACROGENICS INC (MGNX): Completion of Acquisition or Disposition of Assets

MACROGENICS INC (MGNX) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. EX-99.2 3 exhibit99-2proforma.htm EX-99.2 Document Exhibit 99.2 MACROGENICS, INC. UNAUDITED CONSOLIDATED PRO FORMA FINANCIAL INFORMATION Effective as of June 30, 2026, MacroGenics, Inc. (the “Company”) completed the previously announced sale (the “Closing”) of certain assets and

SEC EDGAR 8-K4 min
JUL 2
$MGNXMedAI 8/10

Bora Pharmaceuticals Completes Acquisition of MacroGenics’ Rockville Manufacturing Operations – LiveNews.co.nz

Bora Pharmaceuticals (TWSE:6472; OTCQX:BORAY) said it completed its acquisition of MacroGenics’ Rockville, Maryland GMP biologics drug-substance facility and a Frederick warehousing center for $122.5m via Bora Biologics USA. Bora also signed a long-term CDMO service agreement with MacroGenics. Bora Biologics now has 20,000L SUB capacity across US sites and Taiwan.

livenews.co.nz3 min
JUL 2
$BORAYMedAI 8/10

Bora Pharmaceuticals Completes Acquisition of MacroGenics’ Rockville Manufacturing Operations

Bora Pharmaceuticals (TWSE:6472; OTCQX:BORAY) said it completed its acquisition of MacroGenics’ GMP biologics drug-substance manufacturing operations in Rockville, MD, plus a Frederick, MD warehousing center, for $122.5M via Bora Biologics USA. Bora also signed a long-term CDMO service agreement with MacroGenics and now has 20,000L US SUB capacity across Rockville and San Diego.

sina.com.hk5 min
JUL 2
$MGNXMed

MacroGenics Completes Sale of GMP Manufacturing Operations to Bora Pharmaceuticals

MacroGenics (NASDAQ: MGNX) and Bora Pharmaceuticals (TWSE: 6472; OTCQX: BORAY) said the sale of MacroGenics’ GMP drug substance manufacturing operations to Bora has closed. Bora paid $122.5 million (before fees/expenses and post-closing adjustments). Bora assumed responsibility for Rockville, MD and Frederick, MD operations and hired about 140 employees; a supply agreement covers process development and drug substance production for MacroGenics’ pipeline needs.

manilatimes.net4 min